MedPath

Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation

Phase 2
Completed
Conditions
Ejaculation
Registration Number
NCT00219583
Lead Sponsor
Pfizer
Brief Summary

Assessment of efficacy and safety UK-390,957.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
460
Inclusion Criteria
  • Premature ejaculation as defined by DSM-IV
Read More
Exclusion Criteria
  • History of erectile dysfunction
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Assessment of efficacy and safety
Secondary Outcome Measures
NameTimeMethod
Assessment of quality of sexual life

Trial Locations

Locations (1)

Pfizer Investigational Site

🇹🇷

Balcova, Izmir, Turkey

© Copyright 2025. All Rights Reserved by MedPath